FDMT Stock Analysis: Buy, Sell, or Hold?
FDMT - 4D Molecular Therapeutics, Inc. Common Stock
$9.48
-0.39 (-3.95%)
▼
5d:
-6.88%
30d:
+6.16%
90d:
+26.4%
HOLD
LOW Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
FDMT is down 4.4% this week, but smart money is accumulating calls. Top strike: $7.5 2026-04-17 with 264 OI. Call ratio: 84% View Scanner →
Strength: 5.6/10
Get Alerted When FDMT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: FDMT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: FDMT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: FDMT is currently trading at $9.48, which is considered slightly high relative to its 30-day fair value range of $8.56 to $9.64.
Technical Outlook: Technically, FDMT is in a downtrend. Immediate support is located at $8.45, while resistance sits at $10.71. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: FDMT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $31.33 (+217.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, FDMT is in a downtrend. Immediate support is located at $8.45, while resistance sits at $10.71. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: FDMT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $31.33 (+217.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$8.56 -
$9.64
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
73.7%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.0%)
- BULLISH: Trading 217.5% below Wall St target ($31.33)
- CAUTION: Recommendation downgraded due to -6.9% 5-day decline
Fair Price Analysis
30-Day Fair Range
$8.56 -
$9.64
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$8.45
Resistance Level
$10.71
Current Trend
Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.60
Wall Street Target
$31.33
(+217.5%)
Revenue Growth (YoY)
8508900.0%
Profit Margin
-164.4%
Share & Embed Analysis
Last updated: April 02, 2026 4:06 PM ET
Data refreshes hourly during market hours. Next update: 5:06 PM
Data refreshes hourly during market hours. Next update: 5:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FDMT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Ashoo Gupta
SELL
389 shares
2025-12-20
Scott Bizily
SELL
1635 shares
2025-12-16
Scott Bizily
SELL
1635 shares
2025-11-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 61 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$43 | 65 BUY |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 58 HOLD |
